Table 2.

Characteristics of the proposed drugs in COVID-19 treatment [20, 21, 23••, 25, 27–30]

Agent	Target	Dose	Contraindications	Toxicities	Adjustments	Recommendations
HIDROXYCHLORQUINE	- Immunomodulator. - Blockade of viral entry.	- 400 mg twice daily × 1 day, then 200 mg twice daily × 4 days.	- Myasthenia gravis. - Retinopathy. - Prolonged QT . - IMAOs and quinolones. - Digoxin, antidiabetic, and antiepileptic’s levels modifications. . QTc prolonger drug interactions.	- Common: gastrointestinal intolerance. - Severe: QTc prolongation ♥ , hypoglycemia, hematological alterations, neuropsychiatric and CNS effects, and retinopathy.	- Not-recommended kidney or hepatic adjustment. - May be used in pregnancy if the benefit outweighs the risk. - Cumulative effect: plasmatic half-life: 32 days.	- ECG monitorization. - Hemogram monitorization.
LOPINAVIR/RITONAVIR	- Inhibition of 3-chymotrypsin-like protease. - Type-1 aspartate protease inhibitor.	- 400 mg/100 mg twice daily for up to 14 days.	- Polyurethane feeding-tube contraindicates oral solution. - HIV infection. - Severe hepatic insufficiency. - No-modifiable dugs interaction.	- Common: gastrointestinal intolerance. - Severe: pancreatitis, hepatopathy, QT prolongation. ♥ - 14% of treatment interruptions: gastrointestinal AEs.	- Not-recommended kidney or hepatic adjustment. - May be used in pregnancy unless oral solution.	- Hepatic enzymes monitorization. - PHARMACOLOGICAL INTERACTIONS.
AZITROMIZIN	- Antibacterial: inhibition of protein synthesis.	- 500 mg daily × 3. - 500 mg × 1 + 250 mg daily × 4.	- Macrolide allergy. - Prolonged QT. - Hepatopathy.	- QT prolongation, torsade de pointes, tachyarrhythmia. ♥ - Hepatopathy. - Gastrointestinal symptoms.	- Not-recommended kidney adjustment.	- ECG monitorization. - Hepatic enzymes monitorization.
TOCILIZUMAB	- IL-6 inhibition/reduction.	- 400 mg iv or 8 mg/kg in 1 or 2 doses sparsed 8–12 h.	- Pregnancy. - AST/ALT > 5 times the upper limit. - Neutropenia < 500 cells. - Thrombocytopenia > 50,000 cells. - Transplanted patients or anti-rejection drugs or immunoregulatory drugs - To be included in other C. Trials.	Mild: HTA, headache, respiratory infection, TBC reactivation Severe: anaphylaxis, hepatopathy, hematological reactions, intestinal perforation.	- Not-probed in severe kidney/hepatic impairment.	- IL-6 levels over 20–40 pc/ml. - Alternatively, D-Dimer over 1500 ng/ml.
REMDESIVIR	- RNA polymerase inhibitor.	- 200 mg × 1iv + 100 mg/day × 9.	- Creatinine clearance < 30 ml/min. - AST/ALT > 5 times the upper limit. - Multiorganic failure. - Concomitant antivirals treatment.	- Mild: hepatic or renal failure, gastrointestinal intolerance, hypotension. - Severe (23%): multiorganic failure, acute kidney injury, hepatic failure, sepsis. - Discontinuation (12%)	- Not-recommended kidney or hepatic adjustment. - No probed in severe kidney/hepatic impairment.	- Compassivity uses if saturation < 94%. - Hepatic enzymes and renal function monitorization.
METHYLPREDNISOLONE	- Immunomodulation. - Anti-inflammatory. - Antifibrotic.	- 0.5–1 mg/kg/day up to 7 day. - 250 mg/day up to 3 day.	- Concomitant infection. - Gastrointestinal ulcer.	Severe: hyperglycemia, psychosis, and avascular necrosis.	- Dese de-escalation in chronic treatment. - The patient should meet ARDS criteria	- VERY LIMITED EVIDENCE. - Glycemic control.